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Abstract
Background
Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug
events, hospitalizations, and healthcare spending. This study aimed to address: what exists
regarding polypharmacy management in the European Union (EU); why programs were,
or were not, developed; and, how identified initiatives were developed, implemented, and
sustained.
Methods
Change management principles (Kotter) and normalization process theory (NPT) informed
data collection and analysis. Nine case studies were conducted in eight EU countries: Ger-
many (Lower Saxony), Greece, Italy (Campania), Poland, Portugal, Spain (Catalonia),
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Sweden (Uppsala), and the United Kingdom (Northern Ireland and Scotland). The workflow
included a review of country/region specific polypharmacy policies, key informant interviews
with stakeholders involved in policy development and implementation and, focus groups of
clinicians and managers. Data were analyzed using thematic analysis of individual cases
and framework analysis across cases.
Results
Polypharmacy initiatives were identified in five regions (Catalonia, Lower Saxony, Northern
Ireland, Scotland, and Uppsala) and included all care settings. There was agreement, even
in cases without initiatives, that polypharmacy is a significant issue to address. Common
themes regarding the development and implementation of polypharmacy management ini-
tiatives were: locally adapted solutions, organizational culture supporting innovation and
teamwork, adequate workforce training, multidisciplinary teams, changes in workflow, redef-
inition of roles and responsibilities of professionals, policies and legislation supporting the
initiative, and data management and information and communication systems to assist
development and implementation. Depending on the setting, these were considered either
facilitators or barriers to implementation.
Conclusion
Within the studied EU countries, polypharmacy management was not widely addressed.
These results highlight the importance of change management and theory-based implemen-
tation strategies, and provide examples of polypharmacy management initiatives that can
assist managers and policymakers in developing new programs or scaling up existing ones,
particularly in places currently lacking such initiatives.
Introduction
Morbidity patterns are shifting towards chronic disease [1, 2], and their management has
become a major priority for health systems around the world. Particular concerns arise in
patients with multimorbidity, defined as the coexistence of two or more chronic conditions
in the same individual [3]. Providing care for these patients has a significant impact on health
systems and societies; they utilize more health services [4, 5], are at increased risk of disability
[6], report lower quality of life [7], and die prematurely [8]. Older adults, aged 65 and over,
are more likely to experience multimorbidity [9], although it is increasingly seen in younger
patients [10], and is growing in prevalence [11, 12].
One consequence of multimorbidity is polypharmacy, commonly defined as taking five or
more medications [13]. Polypharmacy has been described as “one of the greatest prescribing
challenges,” [14]. It should be noted that polypharmacy is not always negative, and in many
cases, is the best option for a patient. Therefore, there is rationale for referring to appropriate
polypharmacy (optimal prescribing of multiple medications) or inappropriate polypharmacy
(prescribing multiple medications where the potential harms outweigh the benefits), with less
emphasis on the number of medications a patient is taking [15]. However, polypharmacy does
increase the likelihood of adverse drug events [16, 17], drug interactions, drug-related hospi-
talizations [18], contributes to non-adherence [19], and higher health care costs [20].
Polypharmacy management in Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0195232 April 18, 2018 2 / 20
were part of project SIMPATHY that are not
currently published on our website will be backed
up and accessible to the person monitoring the
email address. The authors confirm that co-
authorship is not required by the SIMPATHY
consortium to gain access to the data.
Funding: This work has been supported by the
SIMPATHY project, grant agreement number
663082 to AM, co-funded by the European
Commission CHAFEA Health Program. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Polypharmacy has been increasing in recent years, due to the rise in the prevalence of multi-
morbidity and an emphasis on single disease clinical practice guidelines on one hand [21, 22],
as well as prolonged life span, and better screening, on the other. For all these reasons, poly-
pharmacy is considered a growing public health issue that needs to be addressed by health care
policymakers throughout the world, including those of the European Union (EU) [23].
Although the impact of inappropriate polypharmacy on health and economic outcomes is
clear, addressing it remains a challenge. There are gaps in the literature regarding care of older
patients with polypharmacy, resulting from the exclusion of older adults from clinical trials,
lack of focus in clinical practice guidelines on issues such as screening and prevention in older
patients, and lack of agreed guidance on the treatment of advanced disease near the end of life
[24]. A meta-analysis evaluating pharmacist interventions in older adults showed improve-
ments in therapeutic outcomes, safety, hospitalizations and adherence, although there was sig-
nificant variability between studies [25]. Similarly, systematic reviews by Patterson [26] and
later updated by Cooper [27] comparing interventions to address polypharmacy in older
patients reported that pharmaceutical care improves prescribing, although there is still uncer-
tainty about what elements make an intervention successful. In addition, the question of how
to successfully implement new polypharmacy management practice models across the full care
continuum has yet to be answered [28].
Project SIMPATHY (Stimulating Innovation Management of Polypharmacy and Adher-
ence in the Elderly) sought to address the issue of inappropriate polypharmacy and related
non-adherence in older patients across the EU by stimulating and supporting innovation
around polypharmacy management. Co-funded by the European Union’s Health Programme,
project SIMPATHY began in June of 2015 and concluded in May of 2017 and was led by the
Scottish Government. The SIMPATHY Consortium was composed of a range of stakeholders
including physicians, pharmacists, health policy makers, health economists, and academic
researchers.
To achieve its goal, a series of three interrelated work streams were conducted with outputs
that included: case studies of the management of polypharmacy; a systematic review of EU
polypharmacy policies and guidelines; an EU benchmarking survey; a Political, Economic,
Sociocultural, Technological, Environmental and Legal (PESTEL) analysis [29]; plus an analy-
sis of the Strengths, Weaknesses, Opportunities, and Threats (SWOT) in consortium coun-
tries; and, an EU-wide modified Delphi survey to validate findings [30, 31]. This report
presents the findings of the case studies.
The aims of the case studies were to address: what exists regarding polypharmacy manage-
ment initiatives in the EU; why they were or were not developed in the current form (the
underlying rationale); and, how any identified initiatives were developed, implemented, and
sustained.
Methods
Case study design
Case study methodology is a set of procedures that can be applied systematically to provide an
in-depth understanding of a specific focus of interest [32]. This design was selected to facilitate
the holistic examination of both the clinical practice and the context surrounding the develop-
ment and implementation of polypharmacy management initiatives.
The eight EU SIMPATHY consortium countries (Germany (Lower Saxony), Greece, Italy
(Campania), Poland, Portugal, Spain (Catalonia), Sweden (Uppsala), and the United Kingdom
(Northern Ireland and Scotland)) were studied using a holistic multiple-case study design
[31]. These European countries were purposefully selected to provide geographic diversity to
Polypharmacy management in Europe
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the SIMPATHY consortium. In case study sites where researchers identified a polypharmacy
management initiative, the initiative (which could be a local, regional, or national initiative)
served as the case and the context for analysis was the country. In sites where no polypharmacy
management initiative was identified, the case was an analysis of the reasons for not having an
initiative, and the context was the country (Fig 1). Polypharmacy management initiatives were
selected based on the knowledge and expertise of local research teams.
Underlying theories and models
There are multiple theories, models, and frameworks in the literature regarding both the
implementation of new clinical practices and leading organizational change [33, 34]. In order
to gain insight into both the change management that drove, and actions that embedded, poly-
pharmacy initiatives into daily practice, we selected one change management model (Kotter’s
Eight Steps Process for Leading Change (Kotter)) and one theory of implementation (Normal-
ization Process Theory (NPT)) to inform both the data collection and analysis [35, 36]. Kotter
describes eight steps to managing change including: creating a sense of urgency; building a
guiding coalition; forming a guiding vision; enlisting a volunteer army; enabling action by
removing barriers; generating short term wins; sustaining accelerations; and instituting
change. NPT has been used to evaluate the implementation of a broad range of complex health
care practices [37–40], and consists of four domains: coherence, cognitive participation, collec-
tive action, and reflexive monitoring. Together, Kotter and NPT provide a rigorous and robust
lens for exploring cases with, and without, polypharmacy management initiatives.
Fig 1. Case study design. HSC: Health and Social Care; NHS: National Health Service.
https://doi.org/10.1371/journal.pone.0195232.g001
Polypharmacy management in Europe
PLOS ONE | https://doi.org/10.1371/journal.pone.0195232 April 18, 2018 4 / 20
Data collection
Data collection in each country occurred in three phases: a desk review of published and grey
literature on polypharmacy management; key informant interviews with experts involved in
the development and implementation of polypharmacy management initiatives; and focus
groups to triangulate findings from both the desk reviews and key informant interviews.
Within each country, a research team consisting of at least one member of the SIMPATHY
consortium was responsible for both data collection and analysis at the local level.
All study participants were provided with an information sheet outlining the specific study
aims and project SIMPATHY in general prior to participating in either the interviews or focus
groups. Written consent for participation and audio-recording was obtained. All interviews
and focus groups were audio-recorded, transcribed verbatim and analyzed in the local lan-
guage, although the final reports were prepared in English. All data was stored on password
protected computers and participant identities were kept anonymous in all reports. All local
institutional review boards were consulted for any ethical issues. Specific approval was pro-
vided by the following ethics boards: Comite´ E´tico de Investigacio´n Clı´nica del Hospital
Clı´nic, Barcelona, Spain; MHH Ethik-Kommission, Hannover, Germany, and; Comissão de
E´tica da Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal. In all other
study sites, there was no need for formal ethics approval as it was either seen as part of service
development and quality improvement, or it did not require official review due to the lack of
involvement of patients and there was no experimental design.
Desk review. Using a structured guide specifically developed for this study, the desk
review was conducted by local research teams between September 2015 and October 2015.
The guide was designed to identify published documents that would shed light on the
development, implementation, and sustainability of any country/region specific polypharmacy
management initiatives. It was developed by the case study coordinators (JM and AA) and
reviewed by members of the SIMPATHY consortium as well as by experts outside the consor-
tium for completeness. Each local research team answered a series of questions within the
guide on the following topics related to the development and implementation of polypharmacy
management initiatives: impact of external economic pressures on the health system; the role
of the government; roles of non-governmental organizations; overview of relevant points of
the healthcare system (e. g. financing, decision making, responsibilities of healthcare profes-
sionals); health information and communication capacity (population level monitoring,
electronic medical records, electronic prescribing); and, details of implementation of a poly-
pharmacy initiative at the institutional level. Documents used to provide data for the desk
review included peer-reviewed publications, government or institutional policies, clinical prac-
tice guidelines, laws and regulations, and government reports.
Key informant interviews. After the desk review was completed, key informants with
knowledge of the development, implementation, and ongoing evaluation of the initiative were
recruited by the local research team. In cases where no polypharmacy initiatives existed, key
informants were those familiar with existing medication management policies and able to
speak to any current and future policy initiatives. Targets for recruitment included at least one
key informant from each of the following groups: policymakers overseeing development of
polypharmacy management policies; health system managers responsible for implementation
at the institution level; and healthcare providers (including physicians, pharmacists, nurses, or
other patient educators). The exact profile mix was determined by researchers within each
case study site and informed by the results of the desk review. To ensure appropriate represen-
tation of stakeholder groups, a proposed list of interviewees and rationale for selection was
reviewed by the study coordinators.
Polypharmacy management in Europe
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Interviews were conducted either face-to-face or by telephone between November 2015 and
January 2016 in the local language using a semi-structured interview guide and lasted approxi-
mately 60 minutes. The interview guide was based on principles from Kotter and NPT, previ-
ously listed, and addressed the rationale for development of the initiative; implementation
strategies; integration into the daily work flow; evaluation; and, plans for future developments.
The guide was reviewed by members of the SIMPATHY consortium both via email and
through phone conversations prior to data collection. Interviewers received both in-person
and web-based training on conducting interviews and in using the guide.
Focus groups. Findings from both the desk review and interviews were analyzed and the
major themes from each site were drawn from these data. To confirm the trustworthiness of
these conclusions, identify any gaps or weaknesses in the reports, and fine tune the final mes-
sages, each research team conducted one focus group between February 2016 and March of
2016 to review the report findings. Focus group recruitment followed the same process as the
key informants. Key informants who had previously been interviewed were eligible for inclu-
sion in the focus group, and as with the interviews, the final mix of profiles depended on the
findings from individual case studies. The target number of participants for the focus groups
was between five and seven people and was scheduled to last for 60–90 minutes. The focus
groups were run by members of the research team with one moderator and one note taker.
Each moderator used a topic guide developed by the study coordinators that was reviewed
using the same process as the interview guide. The topic guide included questions about how
the results in the report matched with personal experience and with what they know of poly-
pharmacy management in their area, if there were any points that had been missed or not
emphasized enough, and if there was anything incorrect in the report. As with the interviews,
moderators also received both in-person and web-based training. See S1 File for additional
information on data collection tools.
Data analysis
Research teams within each country produced a summary report including a narrative
summary of their desk review, analysis of the interview and focus group data, as well as a
time series analysis of key events, and a summary of lessons learned. This was based on
the questions in the desk review topic guide, and a thematic analysis [41] of the interviews
using a deductive coding framework based on Kotter and NPT, pre-agreed by the consor-
tium partners. In addition to the deductive coding, there was an element of inductive
coding, as new themes arose that did not fit within the predetermined framework. Consis-
tency in applying the codes was promoted through consortium-wide training via an in-per-
son workshop and follow up conference calls to discuss questions that arose during the
analysis process. Individual case study reports were written in English using a standardized
template to promote consistency in the type, style and reporting of findings. The study coor-
dinators used these reports to conduct a framework analysis [42] to generate the summary
findings. Each study coordinator independently reviewed the country level reports and
placed major themes within the predefined framework, which was again based on Kotter
and NPT.
Results
Characteristics of polypharmacy initiatives
Five sites had polypharmacy initiatives sufficiently developed for inclusion: Spain (Catalonia),
Germany (Lower Saxony), Sweden (Uppsala), and both of the United Kingdom sites (North-
ern Ireland and Scotland). Two distinct programs were identified for inclusion in Catalonia.
Polypharmacy management in Europe
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Four sites, Greece, Italy (Campania), Poland, and Portugal, did not identify any initiatives or
policies related to polypharmacy, although at the time the study was completed Poland was in
the process of developing a medication use policy that will likely include polypharmacy man-
agement based on a pharmaceutical care model. Tables 1 and 2 provide a summary of the
range of program scope, targets, and objectives in countries with polypharmacy management
initiatives.
Participant characteristics
Across the nine case study sites a total of 75 interviews and 12 focus groups, with a total of 74
participants, were conducted. (In Poland three and in Italy two simultaneous focus groups
were conducted to facilitate conversation between policy makers and managers, healthcare
providers, and patients.) Figs 2 and 3 summarize key informant interview and focus group par-
ticipant characteristics by country and category. Categories are intentionally broad to protect
the identity of key informants.
Table 1. Summary of identified polypharmacy management initiatives.
Country
(region)
Scope; Setting Patients Targeted for
Intervention
Healthcare
Provider
Program Objectives Description of Activities
Spain
(Catalonia)1
Regional;
Primary care
Those meeting health
system definition of
complex chronic
disease
Primary care
physicians
Improve 1) Patient safety and reduce
drug related problems; 2) health
outcomes and control of chronic disease;
3) Adherence and; 4) Healthcare quality
and patient quality of life
• Complex chronic patients flagged in
electronic medical record
• Physicians required to review all flagged
patients according to guidance published
by the Catalan Health Department
Spain
(Catalonia)1
Regional;
Institutional
Admitted to acute
geriatric unit
Geriatrician and
hospital
pharmacist
Improve global patient health and well-
being
• Therapy goals established with patients
and families
• Pharmaceutical care plan developed
accounting for specific diagnosis, the
indication for each medication
(therapeutic, primary or secondary
prevention), and the life expectancy of
the patient
• Care plans shared via fax or verbally with
primary care physicians
Germany
(Lower
Saxony)
Regional pilot;
Community
pharmacy
Determined by
pharmacists but
usually 5
medications and 60
years old
Community
pharmacist
1) minimize drug risks; 2) improve
efficacy of pharmaceutical care; 3)
improve adherence and; 4)
communicate findings with physicians
• Pharmacists choosing to participate
undergo training through their
professional organization sponsoring the
activity
• During two separate patient visits
pharmacists conduct a comprehensive
medication review including adherence
counselling
• Results are communicated to patients
who may choose to share these with their
physician or with patient consent
directly to doctors
1)Two different programs were identified in Catalonia, a government sponsored primary care model and an institutionally sponsored model including inpatient hospital
care, long-term care and nursing homes;
2) includes step-down facilities providing time-limited services geared towards reducing prolonged hospital stays and promoting independence;
3) Scotland has estimated the risk of emergency hospital admission for its population;
4) Sweden has national legislation mandating medication reviews take place but the setting is determined by local health authorities depending on their resources and
need
https://doi.org/10.1371/journal.pone.0195232.t001
Polypharmacy management in Europe
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Characteristics of future polypharmacy initiatives
Amongst the case studies with no polypharmacy management and adherence initiatives, key
informants identified criteria for future initiatives which were similar to those of existing
programs. Most agreed any initiatives should target older patients with frailty, as well as
patients of any age with multiple chronic conditions. There was also agreement that a multidis-
ciplinary approach should be employed. Physicians and pharmacists were the most commonly
mentioned health professionals to implement medication reviews, a fundamental part of poly-
pharmacy management. Similar to countries with existing initiatives, multiple settings for
implementation were mentioned including community pharmacies, primary care, and
Table 2. Summary of identified polypharmacy management initiatives (continued).
Country
(region)
Scope; Setting Patients Targeted for
Intervention
Healthcare
Provider
Program Objectives Description of Activities
United
Kingdom
(Northern
Ireland)
Regional;
Intermediate
care2
Admitted to intermediate care Case management
and consultant
pharmacists
Develop, test and scale up a
regional model for Medicines
Optimization in older people
• Pharmacists working in
intermediate care setting are
supported by a senior consultant
pharmacist in developing patient-
centered pharmaceutical care plans
• Medication adherence assessed
• Care plans communicated with
general practitioner
• Patient followed by pharmacist
post-discharge for up to 30 days
United
Kingdom
(Scotland)
National; Care
homes, Primary
care
All patients in care homes aged
50 or older patients 75 and
older, on 10 or more
medications (one must be high
risk) and at high risk for
hospital admission
Pharmacists and
physicians in
primary care
Systematically address
inappropriate polypharmacy and
adherence across Scotland in order
to minimize harm, optimize
benefits, reduce hospitalizations
and medication waste3
• Apply medication review according
to processes outlined in National
Polypharmacy Guidance
• Guidance addresses establishing
shared treatment goals, evaluating
value of medications based on
number needed to treat, balances
disease state recommendations with
life expectancy, and adherence
Sweden National;
Multiple4
Patients aged 75 with 5 or
more prescription drugs
Physicians or
teams of physicians
and clinical
pharmacists
Increase and ensure the quality,
safety and sustainability of
pharmaceutical care, focusing on
polypharmacy in the elderly
• Guidance and tutorial on
performing medication
reconciliation and comprehensive
medication reviews published by
the National Board of Health and
Welfare, although application is
optional
• Goal of guidance is to optimize the
patient’s medication treatment and
to minimize the incidence of drug-
related problems.
• Changes made based on guidance
should be are communicated orally
and in writing to patients and other
healthcare providers
1) Two different programs were identified in Catalonia, a government sponsored primary care model and an institutionally sponsored model including inpatient
hospital care, long-term care and nursing homes;
2) includes step-down facilities providing time-limited services geared towards reducing prolonged hospital stays and promoting independence;
3) Scotland has estimated the risk of emergency hospital admission for its population;
4) Sweden has national legislation mandating medication reviews take place but the setting is determined by local health authorities depending on their resources and
need
https://doi.org/10.1371/journal.pone.0195232.t002
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hospitals. In Poland and Greece community pharmacies were seen as a particularly important
setting in which to address polypharmacy.
Common themes across case study sites
The framework analysis across case studies revealed a number of themes that were common to
both cases with and without polypharmacy initiatives. Table 3 lists the themes as they relate to
NPT and Kotter, and are detailed below. Depending on the setting, each of these themes could
either be a facilitator or barrier to implementation of a polypharmacy initiative.
Global pressures with local solutions: “We have to start asking ourselves how we are
going to treat [the geriatric population] which will be much larger in 30 years.” Spanish
hospital pharmacist. All case study participants described global, macro level issues that
served to support or hinder the development of polypharmacy initiatives. Amongst these, two
common pressures identified were the need to improve efficiency in the health system and the
need to prepare for an ageing population and subsequent increased complexity of care. In
some situations, this contributed to a sense of urgency, spurring the development of polyphar-
macy initiatives. However, in some case study sites without initiatives, Italy (Campania), Por-
tugal and Greece, pressure to improve economic efficiency was too extreme, and instead of
driving change, created an obstacle. As expressed by a Greek pharmacist, “the main goals for
the hospital are financial” and polypharmacy management was seen as an added “luxury.”
Although each case described the same pressures at the macro level, solutions varied based
on the available resources and culture within the healthcare system. Illustrating the need for
Fig 2. Key informant interview characteristics. 1) The total number of key informants and the total number of
profile characteristics are not equal, as more than one characteristic could be applied to the same key informant (e.g.
one informant could be both a physician and a manager); 2) Those working in governing bodies or agencies
overseeing health systems at a regional or national level; 3) Includes hospital CEO’s, primary care center directors, and
department managers; 4) Geriatricians, hospitalists, general practitioners; 5) Hospital, primary care, and community;
6) Departments of pharmacy and medicine, also includes research and clinical faculty; 7) Medicine and pharmacy; 8)
Patients and representatives of patient associations. UK: United Kingdom.
https://doi.org/10.1371/journal.pone.0195232.g002
Polypharmacy management in Europe
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Fig 3. Focus group participant characteristics. 1) The total number of key informants and the total number of profile
characteristics are not equal, as more than one characteristic could be applied to the same key informant (e.g. one
informant could be both a physician and a manager); 2) Those working in governing bodies or agencies overseeing
health systems at a regional or national level; 3) Includes hospital CEO’s, primary care center directors, and
department managers; 4) Geriatricians, hospitalists, general practitioners; 5) Hospital, primary care, and community;
6) Departments of pharmacy and medicine, also includes research and clinical faculty; 7) Medicine and pharmacy; 8)
Patients and representatives of patient associations. UK: United Kingdom.
https://doi.org/10.1371/journal.pone.0195232.g003
Table 3. Major themes categorized by NPT and Kotter.
Theme NPT Construct Kotter’s Steps
Global pressures with local solutions • Inducted unmatched theme • Inducted unmatched theme
Aligning polypharmacy with other health policy initiatives • Coherence • Build a guiding coalition
• Form strategic vision and initiatives
Organizational culture can help or hinder • Coherence supporting collective action • Enable action by removing barriers
Need for strong data management and ICT • Collective action
• Reflexive monitoring
• Creating urgency
• Generate short term wins
• Sustain acceleration
The role of training the workforce • Coherence
• Cognitive participation
• Collective action
• Enable action
Leading change by sharing leadership Cognitive participation Build a guiding coalition
Creating and implementing multidisciplinary teams Cognitive participation
Collective action
Build a guiding coalition;
Form strategic vision and initiatives
Strategic alignment of financial and human resources Collective action Remove barriers;
Institute change
Strategic policies and legislation Coherence Form strategic vision and initiatives;
Institute change
ICT: information and communication technology
https://doi.org/10.1371/journal.pone.0195232.t003
Polypharmacy management in Europe
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local solutions to the universally identified challenges, a Portuguese physician said, “We can-
not make an accreditation like Northerners based on checklists. That will never work with us,
we are not Scottish.”
Aligning polypharmacy with other strategic initiatives: “If polypharmacy just sat as a
stand-alone prescription project, it would have got lost.” Scottish pharmacist manager.
Of the polypharmacy management initiatives identified, all were developed within the context
of larger initiatives, such as an increased focus on older, more complex patients, medication
safety, or workforce development. In discussions regarding workforce development, expand-
ing the role of pharmacists was specifically mentioned in multiple cases. In Germany, the
Chamber of Pharmacists (the professional association) saw the development of a polyphar-
macy management initiative as an opportunity to both improve the safe use of medications (a
national priority) and for pharmacists to “positively position themselves as a health profes-
sional” (a priority of the Chamber). Aligning polypharmacy management with other strategic
initiatives contributed to coherence, or shared understanding, and facilitated the creation of
guiding coalitions and a shared vision.
Organizational culture can help or hinder: “There is no sense of teamwork in health-
care, medical doctors are not accustomed to cooperation and collaboration.” Greek policy-
maker. Organizational culture was identified by sites with and without polypharmacy
management initiatives as either supporting cognitive participation and subsequent collective
action, or as a barrier that impedes change. In sites with polypharmacy management initia-
tives, there was often a culture of innovation, such as in Northern Ireland, where the Depart-
ment of Health and Medicines Optimisation and Innovation Centre described itself as
“outward looking,” or in Catalonia where a hospital CEO described his job as “managing inno-
vation.” In contrast, in multiple sites without initiatives, the absence of a culture of teamwork
was mentioned repeatedly, such as in Poland, where a pharmacist stated, “Physicians are
unwilling to solve the issue when it is transferred [from a pharmacist to a physician] by a
patient.” Changing organizational culture and improving interprofessional communication
were seen as prerequisites for implementation in Portugal.
The need for strong data management and information and communication technology
(ICT): “One of the most important things is to start measuring drug use, to get a view of
the situation and make healthcare professionals aware of the problem of inappropriate
polypharmacy.” Swedish geriatrician. Consistent across case studies was the need for data
management systems with the capacity to quantify the extent and consequences of polyphar-
macy at a population level, and integrated and networked ICT systems to facilitate implemen-
tation and monitoring at the clinical level. Data management systems were identified in cases
with and without initiatives as critical to generating a sense of urgency and contributing to
coherence. ICT systems also contributed to collective action by facilitating implementation.
This was the case in Catalonia where a primary care manager stated, “One advantage of our
system is that it is completely computerized, you can register everything, and one thing we
have registered is if the patient’s medications have been revised.” Countries or regions without
ICT systems robust enough to monitor polypharmacy, Lower Saxony (Germany), Poland, and
Portugal, identified this as a “main barrier” to implementation stating that there is an “urgent
need” for ICT systems across sectors that support polypharmacy management.
The importance of training the workforce: “Medical education [at the university level]
is not structured and adequate to address the issue of polypharmacy,” Italian physi-
cian. Education was also identified as both a facilitator and barrier to implementation.
Where present, education and training contributed to coherence by creating a common
understanding of the problem. In Scotland and Sweden this was achieved by incorporating
polypharmacy management into the undergraduate training of both pharmacists and
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physicians. Conversely, key informants in Italy, Portugal, and Germany all noted that inade-
quate training was a barrier.
In addition to coherence, education and training also contributed to cognitive participation
by helping each team member identify their role, and facilitated collective action by ensuring
those responsible for implementation had the requisite skills. Having an agency tasked with
continuing professional development, as was the case in Northern Ireland and Scotland (UK),
was noted as instrumental in developing the workforce required for their initiatives.
Leading change by sharing leadership: “You need knowledge of change management to
do this.” Swedish physician and policymaker. Multiple key informants in case studies with
and without polypharmacy management initiatives identified the need for strategic planning
and for leadership at both the management and clinician levels. The importance of leadership
at the clinical level was stressed by a Scottish senior manager who said, “it [the polypharmacy
management program] wasn’t imposed on anybody—the clinicians led it.”
Creating and implementing multidisciplinary teams: “Teamwork is not easy: we need
to find a trade-off between hierarchy and teamwork.” Italian physician. The role and
importance of multidisciplinary teams was echoed across the case studies, and the design and
implementation of these teams mainly fell under cognitive participation and collective action.
Creating a team often involved redefining roles of different healthcare providers (a component
of cognitive participation), a task that proved challenging and sometimes resulted in tension
between different professional groups. A Swedish physician addressed this tension between
pharmacists and physicians noting that, “there are also still some voices against the perfor-
mance of [medication] reviews by a pharmacist.” Pharmacists in Germany were hopeful that
their program would result in “more cooperation on the doctor-pharmacist level” but were
ultimately concerned that their new role might be viewed as trying to “usurp” the role of physi-
cians. In contrast, in Catalonia where the goal of the hospital based program was to “design the
patient’s prescription in a shared way between physicians and pharmacists” there was little or
no tension. In Scotland, outcomes data relieved initial concerns of physicians that pharmacists
were not “able to do the [medication] reviews as well as a general practitioner,” and in Italy
key informants suggested that training and shared clinical objectives could be strategies to pro-
mote team building.
Strategic alignment of financial and human resources: “We will need to change the
dynamic of how we work if we want to do this.” Spanish primary care pharmacist. Reallo-
cating resources to align with polypharmacy management objectives was clearly expressed in all
cases, and can be seen both as an aspect of collective action and a way to facilitate change by
removing barriers. One strategy described in multiple case studies to redistribute human
resources was explicitly devoting physician and pharmacist time to polypharmacy management.
When there was no change in workflow and inadequate time dedicated to a new initiative, such
as in the community pharmacy initiative in Lower Saxony (Germany), implementation was a
challenge. Pharmacists there described doing medication reviews “in their spare time” with one
pharmacist stating, “I have not integrated it correctly.”
The need to align payment systems, contracts, and pay-for-performance incentives with
polypharmacy initiatives was noted in all cases, and a mix of these strategies were seen in the
majority of cases with polypharmacy initiatives. In Germany, community pharmacists did not
get reimbursed by insurance for their services, and this was seen as a barrier to implementa-
tion, even though providing the service resulted in professional satisfaction. In countries with
no initiatives, key informants echoed the sentiments of a Greek policymaker who said that
“more personnel should be hired, or the existing personnel should be better reimbursed for
offering additional services.” Similarly, an Italian pharmacist noted that, “an adjunctive pay-
ment system could be a facilitator of a dedicated [polypharmacy management] service.”
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Strategic policies and legislation: “[Polypharmacy management] is linked in with
Transforming Your Care, the main policy direction in Northern Ireland.” Northern Irish
lead pharmacist. Legislation regulating practice, such as the inclusion of medication reviews
under pharmacists’ scope of practice in Germany or granting prescribing rights to non-physi-
cians in the UK, provided a legal foundation for polypharmacy management in these cases. In
Sweden, legislation was passed specifically requiring medication reviews for patients aged 75
or older taking five or more medications, thereby codifying the management of polypharmacy.
Multiple case studies without initiatives expressed the need for central guidance and policies
directing polypharmacy management. In Poland, the importance of EU policies was men-
tioned by a member of the Chamber of Pharmacy noting the need to “harmonize” policies
throughout Europe.
Policies setting strategic goals for health systems were also credited with supporting the
development of polypharmacy initiatives in all case study locations. These included pharmacy
specific policies, such as Prescription for Excellence in Scotland, as well as general medications
policies, such as the Action Plan for Medication Safety in Germany and the Medicines Optimi-
zation Quality Framework in Northern Ireland, or general health systems policies, like the Cat-
alan Health Plan. In Poland accreditation standards for hospitals state that the “frequency of
polypharmacy cases” must be monitored, which suggests polypharmacy management is per-
formed in accredited hospitals on a regular basis, although no descriptions or evaluations of
these activities were published to date.
Discussion
As part of project SIMPATHY, case studies were conducted in an attempt to describe: what
exists regarding polypharmacy management initiatives; why these programs were developed
in the form they exist; and, how these programs were or were not developed, implemented,
and sustained. A broad range of polypharmacy initiatives across multiple healthcare settings
were identified and, in almost half of case studies, no formal polypharmacy management
activities were noted. Settings for identified polypharmacy management initiatives included
community pharmacies, primary, intermediate, and acute hospital care settings. The role of
different professionals also varied widely, with Scotland and to a certain extent Northern Ire-
land utilizing independent pharmacist prescribers, while implementation in Catalonia (Spain)
and Uppsala (Sweden) focused on physicians and on integrating pharmacists into multidisci-
plinary teams. In contrast, in Germany pharmacists were introduced to the role of medication
checks with little connection to the prescribing doctors.
Even with the variation in approaches to managing polypharmacy, common themes were
identified around the development, implementation, and sustainability of initiatives. These
were common across study sites with and without polypharmacy initiatives, and provide
insight into how and why different programs were developed. The themes included the need
to align polypharmacy with other health system initiatives, create multidisciplinary teams,
ensure education and training is adequate, develop data management and ICT systems to sup-
port monitoring and implementation, reallocate health provider time, and ensure that policies,
legislation, and payment mechanisms are in line with the goals and objectives of the initiative.
These findings are unique within the literature addressing polypharmacy, as we not only
described the variety of clinical practices to address polypharmacy, but also the strategies to
design and implement sustainable solutions.
The range of practice settings identified in this case study are reflective of the variety of
polypharmacy management initiatives described in the literature [24, 25]. A meta-analysis
evaluating pharmacist interventions in older adults in the United States included interventions
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in community pharmacy, ambulatory care, nursing homes and rehabilitation centers, and
inpatient settings [25]. Likewise, a recent Cochrane review included interventions from pri-
mary care, nursing homes, and inpatient units, but none from community pharmacy [26].
Polypharmacy: A complex intervention requiring a systems approach
The breadth of common themes identified and the variety of practice settings point to the fact
that polypharmacy management is a complex intervention [43]. Therefore, these findings
should be considered within the context of other complex, system-level approaches to quality
improvement in healthcare and not simply within the context of a single discipline or depart-
ment. There is significant overlap between the SIMPATHY case study findings and recom-
mendations from major quality improvement frameworks from around the world. The 2001
report from the Institutes of Medicine (IOM) on improving the quality of the US medical sys-
tem, Crossing the Quality Chasm, recommends that organizations should redesign the care
process, improve use of information technology, address knowledge and skill management,
build effective teams, and incorporate performance and outcome measurements [44]. These
echo the specific findings of the case studies around the need to rethink how work gets done,
the role of information technology and data management, the need to address workforce train-
ing, the importance of multidisciplinary teams, and the role of contracts and pay for perfor-
mance to drive change.
The SIMPATHY findings are also similar to the enablers of service delivery reform outlined
by the Health Council of Canada which include 1) leadership at all levels, 2) policies and legis-
lation articulating the vision, 3) capacity-building for health professionals, 4) promotion of
organizational cultures that support innovation and risk taking, and 5) measurement and
reporting to provide continuous feedback [45]. As with the IOM report, the specific findings
of the case studies are reflected here, including the need for shared leadership, the role of policy
and legislation in shaping initiatives and the role of organizational culture in promoting or sti-
fling innovation.
Finally, when viewed through the lens of integrated care, a framework that is increasingly
used to address multimorbidity, there is also considerable overlap. The Rainbow Model of
Integrated Care (RMIC) outlines integration at the system, organization, professional, and
clinical levels [46, 47], which are categories that were all broadly represented in the case stud-
ies. There was significant overlap with the realm of professional integration, with both the case
studies and the RMIC taxonomy identifying the role of health professional training, a focus on
collaboration and teams, and the importance of developing the professional roles of different
providers. All of the commonalities identified between the findings from the SIMPATHY case
studies and other widely used frameworks indicate that these findings should be both relevant
and transferable to multiple settings.
Although there is considerable overlap between the SIMPATHY case studies and estab-
lished quality improvement frameworks, there are also differences. Compared to the RMIC
and its taxonomy, there is much more emphasis in the case studies on professional level inte-
gration, such as creating a shared vision, team building, and interpersonal characteristics.
There was also less emphasis in the case studies on issues related to organizational level inte-
gration when compared to the RMIC. This may be a reflection of the level of maturity of the
polypharmacy management initiatives and policies examined in this study. Most of those
identified were relatively new, and therefore may still be focusing on implementation and the
role of specific professions (such as pharmacists), and not on the larger institutional factors.
This also highlights that, although polypharmacy management can be seen as a component
of integrated care or larger quality improvement initiatives, there are elements unique to its
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implementation that need to be explicitly considered as managers and policymakers look to
address this issue.
Role of theory and change management frameworks to drive
implementation
The case study findings also provide insight into how to support the implementation of com-
plex innovative practices in different settings. The analysis based on Kotter’s principles identi-
fied a density of activity in the early stages of Kotter’s process, specifically around creating a
sense of urgency, a strategic vision, and a guiding coalition, but less in the later stages of insti-
tuting change. Many of the countries without initiatives identified clear barriers to achieving
these crucial first steps (such as lack of data to create a sense of urgency), indicating that a
change management framework might be useful in promoting the development of a polyphar-
macy initiative in these settings.
Analysis based on the NPT constructs provided valuable information regarding implemen-
tation that would not have surfaced within Kotter’s change management principles. The con-
struct of collective action provided a significant wealth of information regarding the need for
the reallocation of resources (both financial and personnel) as well as the challenges of creating
and building multidisciplinary teams. These lessons will be particularly useful to those ready to
move from policy to practice, or to those wishing to refine an existing practice. Together, both
NPT and Kotter provided complementary ways of addressing polypharmacy management.
Although many of the lessons from the SIMPATHY case studies have been discussed in
the context of quality improvement, these principles have not previously been systematically
applied to published polypharmacy management interventions. To date, interventions and
recommendations to address polypharmacy have been primarily focused at the clinical level
looking, for example, at strategies to improve prescribing or patient adherence [48–50]. Many
interventions either fail to take into account, or do not report on, broader systems level issues,
such as the need to change reimbursement models or employ a change management strategy
to speed implementation as was highlighted in this analysis. The similarities between the SIM-
PATHY case study findings and previously published systems level quality improvement rec-
ommendations indicate that, to most effectively address the issue of polypharmacy, a broader
approach that goes beyond clinical level interventions is needed.
The findings from these case studies have practical implications for policymakers and
managers that can be applied across the entire health system to address better polypharmacy
management. These are applicable both to health systems with existing polypharmacy manage-
ment initiatives, and those wishing to develop a new service. These include:
• Build on existing strengths. Those seeking solutions for polypharmacy management should
aim to identify and utilize the strengths of the healthcare system within which they operate
to benefit from existing professional roles, practices and service models.
• Create local solutions. The scope of programs identified highlights the importance of design-
ing local solutions that take into account the existing infrastructure and resources, culture,
and priorities of the health system. The range of initiatives and approaches identified within
the case studies support the idea there is no blueprint or ‘one size fits all’ solution to address-
ing polypharmacy management, and that transferable elements within initiatives should be
tailored to the meet local needs.
• Look for synergies. Polypharmacy management should be integrated into wider health pol-
icy improvement initiatives, nationally, regionally or locally to accelerate change and amplify
the benefit to patients and the healthcare system.
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• Foster a culture of innovation. Work should begin within the existing culture, but efforts
should be made to promote a culture of innovation and quality improvement.
• Invest in data management and ICT. Data management and ICT systems that support moni-
toring, adherence, and implementation are crucial, and lack of these systems presents signifi-
cant barriers to scaling up.
• Ensure education and training better prepares professionals to manage polypharmacy.
Changes in undergraduate, postgraduate, and continuing professional development are
needed to develop the multidisciplinary workforce necessary to address polypharmacy.
• Support development of leadership at all levels. Polypharmacy management is a system wide
issue, and will require a change management strategy and shared leadership between policy-
makers, managers, and clinicians.
• Change how work gets done. Redesigning of workflow, including redistribution of work and
responsibilities between healthcare professionals is essential to implementation.
• Employ multidisciplinary teams. The involvement of multidisciplinary teams employing a
patient-centered approach facilitates the implementation of polypharmacy management.
• Assess current payment schemes. Reimbursement and payment incentives should be aligned
with the goals and objectives of the initiative.
• Create the practice environment with legislation and policy. Legislation and policies are crit-
ical for defining the vision and creating the long-term regulatory environment to support
polypharmacy management initiatives.
Strength and limitations
The case study methodology provided a rich view of polypharmacy management initiatives
in the EU. The combination of the desk review, key informant interviews, and focus groups
provided a deeper understanding of the drivers and barriers to managing polypharmacy. The
context for the cases included in this study were diverse in terms of geography, economies,
sociocultural backgrounds, and covered a broad range of polypharmacy management initia-
tives, making the results transferable to multiple contexts.
The study did have some limitations. Researchers were given leeway in selecting key infor-
mants and focus group participants, and representation of different stakeholder groups was
not uniform across the case study sites. This may have led to bias in data collection. Some
healthcare providers who might play a role in polypharmacy management, such as nurses,
were also underrepresented as key informants. This is partly due to pharmacists, due to their
unique training, being seen as primary drivers in polypharmacy management. The framework
analysis was based on the case study reports, and it is possible that there was inter-coder varia-
tion between sites, although we attempted to minimize this through in-person and online
workshop training with researchers.
Future directions
Given the clear agreement across all case study sites that polypharmacy is a pressing issue,
and the alignment of the SIMPATHY findings with other quality improvement frameworks,
future work should focus on theory based implementation. Researchers should look at the
tools and methods from the field of implementation science and use frameworks such as
the Consolidated Framework for Implementation Research [33] to guide future endeavors.
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Specific topics within the context of implementation include which reimbursement and incen-
tive structures work best to facilitate implementation, what training methods are most success-
ful in creating effective multidisciplinary teams, and how can organizational culture shift to
support innovation.
Conclusion
The policies and processes for addressing polypharmacy vary widely in the EU, and many
countries in the EU are not formally addressing polypharmacy management. These case stud-
ies provide examples of initiatives that can be used by countries in the process of developing
new polypharmacy management activities, as well as to those looking to scale up existing pro-
grams, and highlight the importance of change management and theory based implementation
strategies [30].
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